Evidence map›Paper›PMID 40092518›Full record

ArticleIJTLD open2025

Urgent request for pretomanid label expansion to align with WHO guidelines and improve treatment accessibility and efficacy.

L Kuksa, C Andrejak, B Haecker, G Bothamley, A Calcagno, D M Cirillo, R Duarte, R Fatima, G Ferlazzo, L Guglielmetti and 15 more

Abstract readEditorial
PubMed Full text at PMC Publisher
In one paragraph

Article in IJTLD open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Microbial Clearance of RefractoryPharmaceuticals (Basel, Switzerland) · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors.

L KuksaRiga East University Hospital, Tuberculosis and Lung Disease center, Riga, Latvia.
C AndrejakPneumology Department, University Hospital Centre Amiens-Picardie, Amiens, France.
B HaeckerGerman Central Committee against Tuberculosis (DZK), Berlin, Germany.
G BothamleyHomerton University Hospital, London, UK.
A CalcagnoUnit of Infectious Diseases, Department of Medical Sciences, University of Torino, Torino, Italy.
D M CirilloIRCCS San Raffaele Scientific Institute, Milan, Italy.
R DuarteEPIUnit ITR, Instituto de Saúde Pública da Universidade do Porto, Porto, Portugal.
R FatimaUnited Nations Office for Project Services (UNOPS), Islamabad, Pakistan.
G FerlazzoMédecins Sans Frontières Access Campaign, Geneva, Switzerland.
L GuglielmettiSorbonne Université, Institut national de la santé et de la recherche médicale, Unité 1135, Centre d'Immunologie et des Maladies Infectieuses, Paris France.
G GüntherDepartment of Pulmonology, Allergology and Clinical Immunology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
C HewisonMédecins Sans Frontières, Tuberculosis, Working Group, Paris, France.
C R HorsburghBoston University School of Public Health, Department of Global Health, Boston, MA, USA.
T JägerGerman Center for Infection Research (DZIF), Braunschweig, Germany.
Y KalanchaTB Europe Coalition, Kyiv, Ukraine.
R Otto-KnappGerman Central Committee against Tuberculosis (DZK), Berlin, Germany.
K KranzerClinical Research Department, London School of Hygiene & Tropical Medicine, UK.
T LillebaekInternational Reference Laboratory of Mycobacteriology, Statens Serum Institut, Copenhagen, Denmark.
G MarksThe Woolcock Institute, of Medical Research, Macquarie Park, NSW, Australia.
K MiddelkoopInstitute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town.
I MottaMédecins Sans Frontières Access Campaign, Geneva, Switzerland.
V RabinovaTB Europe Coalition, Kyiv, Ukraine.
P SommerfeldTB Alert, London, UK.
P TattevinInfectious Diseases & Intensive Care Unit, Pontchaillou University Hospital, Rennes, France.
C LangeDepartment of Clinical Infectious Diseases, Research Center Borstel, Leibniz Lung Center, Borstel, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pretomanid is a key anti-TB drug included in the WHO list of essential medications. The current EMA-approved label for pretomanid restricts its use to the regimen comprising bedaquiline, pretomanid and linezolid (BPaL) and only for extensively drug-resistant-TB or multidrug-resistant TB, "when antibiotics used for the latter form of TB do not work or cause unacceptable side effects." This restricted use implies that the older, prolonged and poorly tolerated regimens remain the recommended treatment for most cases of drug-resistant TB. The authors, representing many respiratory groups and societies, call for the label expansion of pretomanid to align with global guidelines, allowing for broader use.

Indexed as

drug resistanceEuropean Medicines AgencyMDR-TBRR-TBtuberculosisXDR-TB

Identifiers

PMID40092518
PMCPMC11906023

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.